Joseph A. Fuchs
Managing Partner
Mr. Fuchs has been a patent attorney since 1989. His practice
includes all aspects of intellectual property law, including
patent prosecution and litigation, patent mapping and
technology licensing agreements. He has extensive legal
IP experience in various complex technology areas,
especially in material sciences, nanotechnology, medical
plastics and other packaging materials, medication
delivery, pharmaceutical formulations, medication error
reduction technologies and internet healthcare.
Mr. Fuchs is a pioneer in patent mapping and has completed numerous patent maps in
highly competitive and complex technology areas for his clients.
He was a former shareholder at Bell Boyd & Lloyd, LLC and Wallenstein & Wagner, Ltd.
Prior to practicing law, Mr. Fuchs was a Station Chemist at the LaSalle Nuclear Power
Plant of Commonwealth Edison. Mr. Fuchs is admitted to the U.S. Patent and
Trademark Office, Illinois State Bar and others.
Mr. Fuchs is currently a member of the Keiretsu Forum (an angel investing group
investing in early stage companies), iBIO and the Association of University Technology
Managers (AUTM).
He received his Bachelor’s Degree of Science in Chemistry from University of Illinois,
Urbana-Champaign, and a J.D. degree from Loyola University of Chicago.
Michael S. Leonard
Partner
Michael S. Leonard concentrates his practice in domestic
and foreign patent prosecution, patent prosecution appeals,
reissues, reexaminations, patent infringement, new product
patent clearance and licensing. Mr. Leonard is a registered
attorney with the U.S. Patent and Trademark Office and is
experienced in technologies involving mechanical,
electrical-mechanical and chemical products. He has
counseled prominent corporations in industries involving
healthcare/medical devices, semiconductors, turbine
engines, home appliances, laser marking, fiber optics, 3-D
modeling, construction equipment, surface and slide fasteners, credit card systems and
composite materials.
Before joining Everest IP Law Group, Mr. Leonard was a shareholder at Bell Boyd and
Lloyd, LLC and Hill & Simpson, PC. He also worked in the legal department at Baxter
Healthcare Corporation. Prior to practicing law, he held technical positions with Baxter
Healthcare Corporation, American Metal Ware Company and Modine Manufacturing
Company.
Mr. Leonard received his undergraduate degree in mechanical engineering from Bradley
University, an M.B.A. with honors from Keller Graduate School of Management and his J.
D. from The John Marshall Law School.
Tin-Chuen Yeung, Ph.D.
Managing Director
Dr. Yeung concentrates his practice in patent prosecution
in biotechnology, pharmaceuticals, bioinformatics,
nanotechnology, medical devices and wireless
communications technology, as well as providing patent
mapping services and IP strategy consultation. He has
been admitted to the U.S. Patent and Trademark Office
since 1995.
In his previous position as Head of Strategic Development of
Life Sciences with the Chicago law firm of Bell, Boyd, and Lloyd, LLC, he was with the
intellectual property group responsible for patent prosecution and client development in
life sciences. He was the Vice Chair of the Biotechnology Committee, Intellectual
Property Law Association of Chicago. Before joining Bell Boyd & Lloyd, Dr. Yeung was
with the Chicago intellectual property law firm Wallenstein & Wagner, Ltd.
Prior to that, Dr. Yeung served as President of Everest International, Inc., a consultant to
Fortune 500 medical technology companies and start-up biotechnology companies. He
has also served as Director of Strategy and Business Development for the Biosciences
Division at Baxter International Inc., where he managed the strategy for world-wide
development, marketing and manufacturing of recombinant protein products. He also
served as Director of Corporate Development for Baxter. In this position he was
responsible for management of Baxter’s acquisitions, technology development, licensing
and strategic alliances. Dr. Yeung was formerly a research fellow at Harvard Medical
School, Department of Pharmacology, studying the action and toxicity of anti-cancer
drugs.
Dr. Yeung is currently a member of the Keiretsu Forum (an angel investing group
investing in early stage companies), iBIO and the Association of University Technology
Managers (AUTM). He also serves on the advisory boards of several companies.
Dr. Yeung holds a BS degree in Biochemistry and a PhD in pharmacology from the State
University of New York, as well as a Master of Management (with Distinction) from
Kellogg Graduate School of Management, Northwestern University, with concentrations
in Finance, Marketing, and Management of Information Systems.
Dr. Yeung speaks and writes fluent Chinese (both Mandarin and Cantonese).
